AB120810
MW 856.89 g/mol, Purity >95%. Potent, selective CCR5 antagonist. Synthetic peptide. Selective antiviral entry inhibitor for R5 tropic HIV-1 isolates. Able to attenuate neuroinflammation.
1 Images
- Chemical Structure
Lab
Chemical Structure - DAPTA, CCR5 antagonist (AB120810)
2D chemical structure image of ab120810, DAPTA, CCR5 antagonist
Properties and storage information
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
Storage information
Store under desiccating conditions|The product can be stored for up to 12 months
Publications (2)
Recent publications for all applications. Explore the full list and refine your search
Frontiers in pharmacology 12:551839 PubMed33953665
2021
miR-4456/CCL3/CCR5 Pathway in the Pathogenesis of Tight Junction Impairment in Chronic Obstructive Pulmonary Disease.
Applications
Unspecified application
Species
Unspecified reactive species
Weiwei Yu,Ting Ye,Jie Ding,Yi Huang,Yang Peng,Qin Xia,Zhang Cuntai
Pathobiology : journal of immunopathology, molecul 86:274-284 PubMed31574524
2019
R5 HIV-1 gp120 Activates p38 MAPK to Induce Rat Cardiomyocyte Injury by the CCR5 Coreceptor.
Applications
Unspecified application
Species
Unspecified reactive species
Rui Gao,Qiujuan Fang,Xi Zhang,Qin Xu,Hanhui Ye,Wenyan Guo,Jiao He,Yahong Chen,Ruixing Wang,Zhijuan Wu,Jing Yu
Complementary Products
Product promise
We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com